News Releases - NervGen Pharma
WEBAug 2, 2024 · NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the …
Homepage - NervGen Pharma
WEBAug 22, 2024 · NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease.
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th …
WEB1 day ago · Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions ...
NervGen Pharma Receives Fast Track Designation for NVG-291 …
WEBOct 23, 2023 · NervGen has initiated a Phase 1b/2a placebo-controlled proof-of-concept trial (NCT05965700) to evaluate the efficacy of NVG-291 in two separate cohorts of individuals with cervical spinal cord injury: chronic (1-10 years post-injury) and subacute (10-49 days post-injury), given demonstrated efficacy in preclinical models of …
NervGen Pharma Announces First Subject Dosed in Landmark …
WEBSep 25, 2023 · NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the...
NervGen Pharma to Present at the 63rd International Spinal Cord …
WEB5 days ago · Vancouver, British Columbia-- (Newsfile Corp. - September 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...
NervGen Pharma Announces Intent to Conduct ... - Business Wire
WEBJan 10, 2022 · NervGen is restoring life’s potential by creating innovative treatments of nervous system damage due to injury or disease. The Company is initially developing treatments for multiple sclerosis ...
NervGen Pharma’s NVG-291-R Demonstrates Significant
WEBJul 28, 2022 · NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due...
NervGen Pharma Announces First Subject Dosed in Landmark …
WEBSep 25, 2023 · NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.
NervGen Cleared to Enroll Final Group in Trial of NVG-291
WEBMay 13, 2022 · NervGen Pharma has received approval to enroll a third and final group of healthy volunteers in the multiple ascending dose (MAD) segment of its Phase 1 clinical trial of NVG-291, an...
Skip to content